Terminal Value differences between EBITDA and Perpetuity Method (within DCF Model)

I've been practicing valuing some public companies using the DCF Model, and I'm using both the EBITDA and Perpetuity Method to come up with a terminal value. However, I'm noticing huge discrepancies between the two methods.

Is this normal? And when should one use one method over the other?

1 Comments

Greg Marmalard

HF

9y

Debitis id est dolores fugiat nemo id. Animi excepturi voluptatem aut illo quia. Laudantium expedita tempore fugiat deleniti voluptates illo.

Reply

Quote

Report

Other

+32	Does anyone else find it very difficult to take vacations in ER?	5	1w
+16	Intel (INTC): My Bull Case Still Doesn't Justify the Current Stock Price	2	2w
+15	Built a desktop valuation app (DCF / DDM / reverse DCF) so I'd stop rebuilding Excel models for every pitch — would value some ER feedback	3	4d
+15	Started ER Internship, Reconsidering: Exit Opps?	2	3d
+11	Thoughts on boutique ER firm opportunity and options afterwards	2	2w
+11	PayPal (PYPL): Why Is the Market Valuing PayPal Like a Low-Growth Company Despite Strong Free Cash Flow?	2	1w
+9	Rising Sophomore clueless about recruiting timeline	3	2w
+8	Biopharma ER?	3	4d
+7	Why hire an equity analyst if AI can write the reports	2	6d
+6	Advice for a new associate?	1	6d

Career Resources

See All Comments - 100% Free